Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Perrigo Rises to Highest in More Than a Month on FDA Hearing

Feb. 29 (Bloomberg) -- Perrigo Co. rose to the highest level in six weeks in Tel Aviv as the U.S. Food & Drug Administration is considering rule changes that would allow more prescription drugs to be sold over-the-counter.

The shares of the maker of over-the-counter drugs rose 2.8 percent to 379.30 shekels, the highest since Jan. 19, at the 4:30 p.m. close in Tel Aviv. The shares have gained 7.5 percent this week.

“It’s definitely an interesting development to see the FDA proactive about switching drugs and not just responding to requests or applications,” said Jonathan Kreizman, analyst at Clal Finance Batucha Brokerage Ltd.

The FDA will hold a public hearing on the matter next month, it said on its website earlier this week.

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.